KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Current Leases (2019 - 2025)

Arbutus Biopharma's Current Leases history spans 10 years, with the latest figure at $531000.0 for Q3 2025.

  • For Q3 2025, Current Leases rose 13.46% year-over-year to $531000.0; the TTM value through Sep 2025 reached $531000.0, up 13.46%, while the annual FY2024 figure was $483000.0, 13.65% up from the prior year.
  • Current Leases for Q3 2025 was $531000.0 at Arbutus Biopharma, up from $514000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $563000.0 in Q1 2025 and bottomed at $357000.0 in Q2 2021.
  • The 5-year median for Current Leases is $439000.0 (2021), against an average of $445250.0.
  • The largest annual shift saw Current Leases fell 2.87% in 2022 before it grew 14.25% in 2023.
  • A 5-year view of Current Leases shows it stood at $383000.0 in 2021, then decreased by 2.87% to $372000.0 in 2022, then grew by 14.25% to $425000.0 in 2023, then grew by 13.65% to $483000.0 in 2024, then increased by 9.94% to $531000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Current Leases are $531000.0 (Q3 2025), $514000.0 (Q2 2025), and $563000.0 (Q1 2025).